Payment overview · 2025
General Payments
$1,054.85
27 reported records · 6 companies
Healthcare provider profile · identity verified
David N Catlett, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1245295310
Verified facts
What the public records show
CMS Open Payments records show David N Catlett, MD received $1,054.85 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Nurtec Odt, Ozempic, Ubrelvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $307.28 | 29.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $248.97 | 23.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.87 | 15.2% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 11.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.02 | 11.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.72 | 8.9% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,054.85 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.50 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $129.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $120.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.09 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.72 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.72 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.49 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 277 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 258 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 234 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
258 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
234 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
277 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1128 | 337 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 166 |
| Lisinopril | Lisinopril | 510 | 144 |
| Omeprazole | Omeprazole | 483 | 131 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 396 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 117 |
| Furosemide | Furosemide | 355 | 112 |
| Metformin Hcl Er | Metformin Hcl | 330 | 101 |
| Losartan Potassium | Losartan Potassium | 302 | 86 |
| Simvastatin | Simvastatin | 294 | 81 |
| Trazodone Hcl | Trazodone Hcl | 294 | 71 |
| Potassium Chloride | Potassium Chloride | 292 | 80 |
| Gabapentin | Gabapentin | 287 | 75 |
| Eliquis | Apixaban | 277 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 93 |
| Meloxicam | Meloxicam | 262 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 74 |
| Farxiga | Dapagliflozin Propanediol | 258 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 244 | 66 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 244 | 79 |
| Ozempic | Semaglutide | 234 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 72 |
| Allopurinol | Allopurinol | 207 | 63 |
| Carvedilol | Carvedilol | 207 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 59 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 198 | 40 |
| Montelukast Sodium | Montelukast Sodium | 178 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 47 |
| Jardiance | Empagliflozin | 163 | 40 |
| Mirtazapine | Mirtazapine | 161 | 40 |
| Alendronate Sodium | Alendronate Sodium | 158 | 47 |
| Metformin Hcl | Metformin Hcl | 155 | 45 |
| Sertraline Hcl | Sertraline Hcl | 155 | 50 |
| Doxepin Hcl | Doxepin Hcl | 153 | 36 |
| Glimepiride | Glimepiride | 147 | 42 |
| Ezetimibe | Ezetimibe | 144 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 143 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 45 |
| Promethazine Hcl | Promethazine Hcl | 136 | 33 |
| Nortriptyline Hcl | Nortriptyline Hcl | 134 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 132 | 41 |
| Tramadol Hcl | Tramadol Hcl | 127 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 27 |
| Topiramate | Topiramate | 126 | 29 |
| Valsartan | Valsartan | 126 | 35 |
| Methylprednisolone | Methylprednisolone | 125 | 109 |
| Pregabalin | Pregabalin | 124 | 25 |
| Buspirone Hcl | Buspirone Hcl | 123 | 32 |
| Clonazepam | Clonazepam | 120 | 27 |
| Alprazolam | Alprazolam | 119 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 114 | 22 |
| Bupropion Xl | Bupropion Hcl | 107 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 106 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 103 | 86 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 26 |
| Mounjaro | Tirzepatide | 101 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 98 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 26 |
| Januvia | Sitagliptin Phosphate | 87 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 84 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 18 |
| Prednisone | Prednisone | 79 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 22 |
| Ibuprofen | Ibuprofen | 77 | 21 |
| Synthroid | Levothyroxine Sodium | 77 | 17 |
| Famotidine | Famotidine | 76 | 28 |
| Linzess | Linaclotide | 74 | 21 |
| Spironolactone | Spironolactone | 74 | 23 |
| Cephalexin | Cephalexin | 73 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 22 |
| Baclofen | Baclofen | 71 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 71 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 20 |
| Torsemide | Torsemide | 70 | 25 |
| Fluconazole | Fluconazole | 69 | 38 |
| Finasteride | Finasteride | 68 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 65 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 17 |
| Klor-Con M20 | Potassium Chloride | 63 | 24 |
| Methocarbamol | Methocarbamol | 63 | 29 |
| Warfarin Sodium | Warfarin Sodium | 63 | 14 |
| Meclizine Hcl | Meclizine Hcl | 62 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 46 |
| Xarelto | Rivaroxaban | 60 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Cefdinir | Cefdinir | 52 | 39 |
| Bumetanide | Bumetanide | 51 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | 18 |
| Estradiol | Estradiol | 50 | 15 |
| Ondansetron Odt | Ondansetron | 50 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Amoxicillin | Amoxicillin | 49 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 19 |
| Rybelsus | Semaglutide | 49 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 16 |
| Irbesartan | Irbesartan | 47 | 15 |
| Midodrine Hcl | Midodrine Hcl | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Myrbetriq | Mirabegron | 44 | 11 |
| Naproxen | Naproxen | 42 | 12 |
| Nitroglycerin | Nitroglycerin | 42 | 29 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | 14 |
| Aripiprazole | Aripiprazole | 40 | 13 |
| Diazepam | Diazepam | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 17 |
| Glipizide | Glipizide | 39 | 12 |
| Loperamide | Loperamide Hcl | 38 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 15 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 36 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 24 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Nystatin | Nystatin | 33 | 22 |
| Varenicline Tartrate | Varenicline Tartrate | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 30 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Hydrocortisone | Hydrocortisone | 30 | 15 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Colchicine | Colchicine | 29 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 12 |
| Ibu | Ibuprofen | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 14 |
| Estradiol (Once Weekly) | Estradiol | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 25 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Pilocarpine Hcl | Pilocarpine Hcl | 21 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,054.85 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, FARXIGA, Kerendia, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, Wegovy, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error